Fasting + Senolytic Agents (e.g., Fisetin, Dasatinib + Quercetin) Protocol

The combination of fasting with senolytic agents like Fisetin or Dasatinib plus Quercetin (D+Q) is an emerging approach in longevity science aimed at supporting healthier aging by targeting cellular senescence. This protocol is gaining attention for its potential to reduce the burden of senescent cells—cells that have stopped dividing but remain metabolically active and contribute to tissue dysfunction and chronic inflammation. While still largely in the research and early clinical stages, this combined strategy may be relevant for individuals interested in precision longevity interventions, especially those concerned with age-related decline, metabolic health, or chronic inflammatory conditions.

How It Works

To understand the Fasting + Senolytic Agents Protocol, it helps to first know a bit about senescent cells. These cells accumulate over time and release a range of inflammatory molecules known as the senescence-associated secretory phenotype (SASP). SASP factors can disrupt tissue function and promote aging-related diseases.

This protocol uses two complementary mechanisms to address senescent cells:

• Senolytic Agents: Compounds like Fisetin (a natural flavonoid) and the drug combination Dasatinib plus Quercetin selectively induce programmed cell death (apoptosis) in senescent cells. They do this by interfering with the survival pathways that these cells rely on, such as BCL-2 and PI3K/AKT signaling. By targeting these pathways, senolytics encourage senescent cells to self-destruct without harming healthy cells.

• Fasting: Whether intermittent or periodic, fasting triggers a metabolic state that activates autophagy—a natural process where the body clears out damaged proteins and organelles. Fasting also creates nutrient deprivation and mild metabolic stress that can sensitize senescent cells, making them more susceptible to clearance by senolytic agents. Additionally, fasting reduces systemic inflammation, which complements the inflammation-lowering effects of senolytics.

Together, these mechanisms may synergize to more effectively reduce senescent cell load, dampen harmful inflammation, and promote tissue repair and rejuvenation.

What the Evidence Says

Research into senolytic agents and fasting individually has shown promising results in preclinical studies, including animal models of aging and disease. For example, Fisetin and Dasatinib plus Quercetin have been observed to reduce senescent cell markers, improve tissue function, and extend healthspan in mice. Fasting similarly supports cellular recycling processes and metabolic health.

More recently, studies from 2024 to 2026 have explored the combined use of fasting and senolytics. Early clinical trials and preclinical data suggest that combining these approaches may amplify benefits—enhancing senescent cell clearance and reducing inflammation more than either treatment alone. However, this evidence is still emerging (categorized as Tier 3, or T3, evidence), and larger, longer-term human studies are needed to confirm safety, optimal dosing, and efficacy.

It is also important to note that senolytic agents can have side effects and their use should be carefully managed under medical supervision. The ideal fasting protocols to pair with senolytics are still being defined, and individual responses may vary.

Clinical Context

In clinical or precision longevity settings, the Fasting + Senolytic Agents Protocol is typically employed under the guidance of a qualified healthcare provider or physician experienced in longevity medicine. The protocol involves carefully timed fasting periods combined with senolytic dosing schedules designed to maximize senescent cell clearance while minimizing risks.

Common scenarios where this protocol might be considered include:

• Individuals with age-related tissue dysfunction or chronic low-grade inflammation
• Those with metabolic syndrome or early-stage osteoarthritis seeking supportive interventions
• Patients interested in experimental approaches to mitigate cardiovascular aging or neurodegeneration (though evidence here remains preclinical)

Monitoring usually involves assessment of inflammatory markers, metabolic health parameters, and potential side effects related to senolytic agents. Because senolytics target specific cell survival pathways, personalized dosing and timing are important to balance effectiveness with safety.

Importantly, this protocol is not a standard clinical practice at this time but rather an emerging option within precision longevity frameworks. Anyone considering it should do so only with physician supervision and as part of a comprehensive health plan.

Key Takeaways

• The Fasting + Senolytic Agents Protocol combines fasting-induced autophagy and metabolic stress with senolytic compounds to target and clear senescent cells.
• Senolytic agents like Fisetin and Dasatinib plus Quercetin selectively promote apoptosis in senescent cells by disrupting their survival pathways.
• Early research suggests the combination may synergistically reduce inflammation and improve tissue function, but more human studies are needed.
• This approach should be undertaken only with guidance from a qualified healthcare provider experienced in longevity medicine.

Frequently Asked Questions

Q: Are senolytic agents like Fisetin safe to take during fasting?
A: When used as part of a supervised protocol, senolytic agents can be timed to coincide with fasting periods to potentially enhance their effects. However, safety and dosing should always be overseen by a qualified healthcare provider.

Q: How often is the fasting + senolytic protocol typically done?
A: Protocols vary, but intermittent or periodic fasting combined with senolytic dosing is generally done in cycles (e.g., a few days of fasting followed by senolytic administration). Specific schedules depend on individual health status and physician guidance.

Q: Can this protocol reverse aging?
A: While research suggests it may support healthier aging by reducing senescent cell burden and inflammation, it is not a cure or reversal of aging. Its effects are best seen as part of a broader longevity strategy under medical supervision.